Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price boosted by investment analysts at Bank of America ...
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC ...
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a ...
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...